In two independent cohorts, e-Lung automated biomarkers are highly prognostic, outperforming FVC confirming previous findings in patients with IPF. Clinical trial endpoints combining e-Lung imaging biomarkers with FVC may improve definition of treatment response in ILD; this is being explored in prospective clinical trials.